JPMorgan Chase & Co. (NYSE: JPM) is slated to report third quarter 2019 earnings results on Tuesday, October 15, before the market opens. The company is expected to report earnings of $2.45 per share. This compares to earnings of $2.34 per share reported a year earlier. Revenue is expected to grow 2.4% year-over-year to $28.4 billion.
The banking industry is dealing with lower interest rates which are likely to pressurize net interest margins. More rate cuts are expected to take place this year, adding to the uncertainty. Investors should watch out for updates on credit conditions as well as loan growth prospects. The general economic trends and their impact on debt repayments are also an important area to keep an eye on.
Last quarter, JPMorgan saw strength in its consumer banking business while the investment banking and commercial banking divisions saw weakness. Wealth management remained relatively flat due to lower investment valuation gains. In the third quarter, net interest income might be impacted by the drop in interest rates.
Despite the uncertain environment, JPMorgan’s quarterly results are likely to remain steady as the company continues to grow its market share and expand its footprint. The bank is also expected to benefit from its investments in building its technological and digital banking capabilities.
In the second quarter of 2019, JPMorgan beat revenue and earnings estimates. Revenues grew 4% year-over-year to $28.8 billion and EPS improved 23% to $2.82. The company saw a 22% growth in its Consumer & Community Banking division while the remaining segments posted single-digit declines.
JPMorgan’s shares have gained 21% year-to-date. The majority of analysts have given the stock a Buy rating and the average price target is $122.10.
JPMorgan’s competitors Goldman Sachs (NYSE: GS) and Wells Fargo (NYSE: WFC) are also scheduled to report their earnings results on the same day.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
